Narrow search
Showing 1 - 10 of 36,689
Cover Image
Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
Nuijten, Mark; Meester, Liebeth; Waibel, Franz; Wait, … - In: PharmacoEconomics 16 (1999) 4, pp. 379-397
therapy to death, and to generate estimates of the cost and effectiveness of letrozole and megestrol in order to determine the … letrozole compared with standard care with megestrol. The model was based on clinical trial results showing a clear advantage of … letrozole and megestrol, respectively. The analysis covered the period from treatment initiation until death (lifetime model …
Persistent link: https://www.econbiz.de/10005449176
Cover Image
A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy: For Advanced Breast Cancer in Postmenopausal Patients
Karnon, Jon; Jones, Trefor - In: PharmacoEconomics 21 (2003) 7, pp. 513-525
Background: Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first … comparing letrozole and tamoxifen as first-line hormonal therapies in postmenopausal women diagnosed with advanced breast cancer … in year 2000 values. Results: The baseline results showed that letrozole is a cost-effective alternative to tamoxifen …
Persistent link: https://www.econbiz.de/10005449103
Cover Image
Cost-Effectiveness Analysis of Exemestane Compared with Megestrol in Advanced Breast Cancer: A Model for Europe and Australia
Lindgren, Peter; Jonsson, Bengt; Redaelli, Alberto; … - In: PharmacoEconomics 20 (2002) 2, pp. 101-108
megestrol for postmenopausal women with progressive advanced breast cancer after therapy with tamoxifen. …Objective: To investigate the cost effectiveness of exemestane compared to megestrol in post-menopausal women after … tamoxifen failure. Design and setting: A modelling study from the third-party payer perspective in Australia, Belgium, France …
Persistent link: https://www.econbiz.de/10004990329
Cover Image
Tamoxifen Plus Chemotherapy versus Tamoxifen Alone as Adjuvant Therapies for Node-Positive Postmenopausal Women with Early Breast Cancer: A Stochastic Economic Evaluation
Karnon, Jonathan; Brown, Jackie - In: PharmacoEconomics 20 (2002) 2, pp. 119-137
simulation (DES) model that compared tamoxifen plus chemotherapy versus tamoxifen alone in node-positive postmenopausal women … results show that the addition of chemotherapy to tamoxifen in this patient group is relatively cost effective (under Lstg … 10% of observations in which tamoxifen dominates tamoxifen plus chemotherapy. Conclusions: The results demonstrate the …
Persistent link: https://www.econbiz.de/10005590280
Cover Image
The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer: The Lahey Guidelines
Hughes, Kevin S.; Roche, Constance A.; Whitney, Timothy; … - In: Disease Management and Health Outcomes 7 (2000) 4, pp. 201-215
Most breast and ovarian cancers occur sporadically, but an estimated 5 to 10% of cases occur in women with hereditary predisposition to these cancers. Two genes, BRCA1 and BRCA2, have been identified, which, when altered, are thought to be responsible for most cases of hereditary breast and...
Persistent link: https://www.econbiz.de/10005590121
Cover Image
New Generation Aromatase Inhibitors in Breast Cancer: Weighing Out Potential Costs and Benefits
Higa, Gerald M. - In: PharmacoEconomics 17 (2000) 2, pp. 121-132
activity, but also to the unparalleled success of tamoxifen. The present status, emerging roles and concerns of the new …
Persistent link: https://www.econbiz.de/10005449281
Cover Image
Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK
Brown, Ruth E.; Hutton, John; Burrell, Anita - In: PharmacoEconomics 19 (2001) 11, pp. 1091-1102
Objective: To compare clinical and economic study data for docetaxel, paclitaxel and vinorelbine in the treatment of anthracycline-resistant advanced breast cancer. Study design and methods: A Markov decision-analysis model to simulate the clinical course of a `typical' patient with advanced...
Persistent link: https://www.econbiz.de/10005590325
Cover Image
Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer: A Need for Improved Modelling to Aid Decision Making
Annemans, Lieven - In: PharmacoEconomics 26 (2008) 5, pp. 409-423
of 5 years of tamoxifen. However, several options are available in terms of treatment schedule and selected drug …
Persistent link: https://www.econbiz.de/10005243123
Cover Image
Aromatase Inhibitors in Breast Cancer: A Review of Cost Considerations and Cost Effectiveness
Karnon, Jonathan - In: PharmacoEconomics 24 (2006) 3, pp. 215-232
these agents appear to have clinical superiority, they are more expensive than the therapies (primarily tamoxifen) they have … appear cost effective compared with current practice. An analysis in the advanced setting suggests that letrozole may be the …
Persistent link: https://www.econbiz.de/10005590282
Cover Image
Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy: The UK Perspective
Karnon, Jonathan; Delea, Thomas; Johnston, Stephen R.D.; … - In: PharmacoEconomics 24 (2006) 3, pp. 237-250
Background: MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor …' adjuvant tamoxifen therapy. The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate … the lifetime cost effectiveness of letrozole in this setting. Methods: A Markov model was used to estimate the incremental …
Persistent link: https://www.econbiz.de/10005404967